Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Ginkgo Biloba | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Ongoing; no cycling required. Clinical trials typically run 22-26 weeks. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | strong_human | moderate_human |
Standardized extract (EGb 761) contains flavonoid glycosides (24%) and terpene lactones (6% — ginkgolides A/B/C and bilobalide) that act through multiple pathways: potent free radical scavenging and inhibition of membrane lipid peroxidation; antagonism of platelet-activating factor (PAF) via ginkgolides; enhancement of cerebral blood flow through nitric oxide-mediated vasodilation and reduced blood viscosity; and increased prefrontal dopamine and acetylcholine release via acylated flavonol glycosides. Bilobalide provides direct neuroprotection against excitotoxicity and mitochondrial dysfunction.
120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses
With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest.
Ongoing; no cycling required. Clinical trials typically run 22-26 weeks.
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →